B-type natriuretic peptide predicts left atrial appendage thrombus in patients with nonvalvular atrial fibrillation

Echocardiography

Volumn 30, Issue 8, 2013, Pages 889-895

  Doukky, Rami ^a,b   Gage, Heather ^a   Nagarajan, Vijaiganesh ^b   Demopoulos, Anna ^a   Cena, Marek ^b   Garcia Sayan, Enrique ^a   Karam, George J ^a   Kazlauskaite, Rasa ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Jr Hospital of Cook County   (United States)

Author keywords

atrial fibrillation; B type natriuretic peptide (BNP); CHADS2 score; left atrial thrombus; transesophageal echocardiogram (TEE)

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; ECHO CONTRAST MEDIUM;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ATRIAL FIBRILLATION; B-TYPE NATRIURETIC PEPTIDE (BNP); CHADS2 SCORE; LEFT ATRIAL THROMBUS; TRANSESOPHAGEAL ECHOCARDIOGRAM (TEE);

ATRIAL APPENDAGE; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; FEMALE; HEART VALVE DISEASES; HUMANS; ILLINOIS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THROMBOSIS;

EID: 84883739666     PISSN: 07422822     EISSN: 15408175     Source Type: Journal    
DOI: 10.1111/echo.12169     Document Type: Article

References (25)

1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48: 854-906.
2. Archer SL, James KE, Kvernen LR, et al. Role of transesophageal echocardiography in the detection of left atrial thrombus in patients with chronic nonrheumatic atrial fibrillation. Am Heart J 1995; 130: 287-295.
3. Caplan LR, D'Cruz I, Hier DB, et al. Atrial size, atrial fibrillation, and stroke. Ann Neurol 1986; 19: 158-161.
4. Bernhardt P, Schmidt H, Hammerstingl C, et al. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol 2005; 45: 1807-1812.
5. Leung DY, Black IW, Cranney GB, et al. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol 1994; 24: 755-762.
6. Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998; 31: 1622-1626.
7. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
8. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 2287-2292.
9. Lip GY,: The balance between stroke prevention and bleeding risk in atrial fibrillation: A delicate balance revisited. Stroke 2008; 39: 1406-1408. PubMed PMID: 18323477. Epub 2008/03/08. eng.
10. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
11. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.
12. Bakowski D, Wozakowska-Kaplon B, Opolski G,: The influence of left ventricle diastolic function on natriuretic peptides levels in patients with atrial fibrillation. Pacing Clin Electrophysiol 2009; 32: 745-752.
13. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463.
14. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
15. Teichholz LE, Kreulen T, Herman MV, et al. Problems in echocardiographic volume determinations: Echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976; 37: 7-11.
16. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med 1998; 128: 639-647.
17. Bernhardt P, Schmidt H, Hammerstingl C, et al. Patients at high risk with atrial fibrillation: a prospective and serial follow-up during 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Soc Echocardiogr 2005; 18: 919-924.
18. Kamp O, Verhorst PM, Welling RC, et al. Importance of left atrial appendage flow as a predictor of thromboembolic events in patients with atrial fibrillation. Eur Heart J 1999; 20: 979-985.
19. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-691.
20. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-2078.
21. Shimizu H, Murakami Y, Inoue S, et al. High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation. Stroke 2002; 33: 1005-1010.
22. Watanabe D, Shizuka K, Koyama S, et al. Plasma brain natriuretic peptide levels indicating thromboembolism in very elderly patients with non-valvular atrial fibrillation. Circ J 2007; 71: 1446-1451.
23. Demopoulos A, Gage H, Cena M, et al. Diastolic dysfunction mediates left atrial appendage thrombus formation in patients with atrial fibrillation. J Am Coll Cardiol 2011; 57 (14A): 48.
24. Bayard YL, Omran H, Neuzil P, et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: Results from the European PLAATO study. EuroIntervention 2010; 6: 220-226.
25. Holmes DR Jr, Schwartz RS,: Left atrial appendage occlusion eliminates the need for warfarin. Circulation 2009; 120: 1919-1926; discussion 26.